Entrada Therapeutics Inc., a Boston, MA-based biotechnology company dedicated to advancing treatment of devastating diseases using intracellular biologics, closed a $116m Series B financing.
The round was led by Wellington Management Company. Wellington Management was joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority (“QIA”), Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures and one undisclosed global investment firm. Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital also participated in the financing.
Led by Dipal Doshi, President and Chief Executive Officer, Entrada Therapeutics leverages its proprietary Endosomal Escape Vehicle (EEV)TM platform to create a diverse pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases.
The company plans to use the funds to advance its diverse pipeline to the clinic. Included in this pipeline are several of Entrada’s oligonucleotide programs for the treatment of multiple neuromuscular diseases, led by Duchenne muscular dystrophy (DMD). In addition, the company is applying its proprietary Endosomal Escape Vehicle (EEV)TM platform to expand beyond neuromuscular diseases into additional therapeutic areas.